Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study

Table 3

Relative dose intensity of Adriamycin, cyclophosphamide, and paclitaxel among breast cancer patients on AC and AC-T regimen at TASH, from January 1 to September 30, 2017 GC.

Drug	Dosing	N	RDI (%)	Range	N (%) of patients with
					RDI < 85%	Overall RDI ≥ 85%
A	60 mg/m^2Q3W for 4 or 6 cycles	146	90.40 ± 8.876	59.57–101.61	38 (26)	102 (69.9)
C	600 mg/m^2 Q3W for 4 or 6 cycles	146	90.40 ± 8.876	59.57–101.61	38 (26)
T	175 mg/m^2Q3W for 4 cycles	75	93.35 ± 8.592	53.50–102.44	9 (12)

A = Adriamycin; C = cyclophosphamide; Q3W = every three weeks; RDI = relative dose intensity; T = paclitaxel 44 (30.1%) of the patients had overall RDI < 85%.